Background and Objective. There seems to be a strong causal relationship be
tween allergy and the origins of asthma. Susceptibility to both is determin
ed by a combination of genetics and environment acting through a complex ne
twork of cytokines. Nearly 90% of affected children have positive skin test
s indicating the presence of specific immunoglobulin E (IgE), with sensitiv
ity to house dust mite, Alternaria, cockroach, cat, and dog most closely li
nked to the disease. Greater exposure to house dust mite during infancy lea
ds to earlier onset of wheezing, and elevated serum IgE levels correlate wi
th the appearance of asthma symptoms. Specific IgE binds to high-affinity (
Fc epsilon RI) receptors on mast cells and basophils. The IgE-mediated reac
tions that follow exposure of sensitized mast cells to an allergen are desi
gnated early- and late-phase asthmatic responses (EAR and LAR). EAR is char
acterized by release of histamine and other preformed mediators within 1 ho
ur of allergen exposure. It is often followed by LAR, an infiltration of th
e airways by inflammatory cells associated with an episode of more prolonge
d, and usually more severe airflow obstruction, 4 to 8 hours after antigen
exposure. Chronic airway symptoms result from persistent LAR caused by cont
inuous allergen exposure. IgE antibodies are capable of passive transfer of
both EAR and LAR sensitivity. IgE-mediated mast cell activation contribute
s to chronic tissue eosinophilia and airway remodeling, with permanent loss
in pulmonary function.
Omalizumab (rhuMAb-E25) is a recombinant, humanized, monoclonal anti-IgE an
tibody of mouse origin developed for the treatment of IgE-mediated diseases
. Omalizumab binds to free IgE at the same site as the high-affinity recept
or. Although it attaches to free IgE, it does not bind to IgA, IgG, or cell
-bound IgE. It therefore does not induce cross-linking of cell-bound IgE, w
hich would lead to the release of allergic mediators. It has been reported
to decrease serum IgE levels in a dose-dependent manner, inhibit EAR and LA
R, and cause a down-regulation of Fc epsilon RI receptors on basophils. Oma
lizumab has been reported to be safe and effective in improving asthma cont
rol and reducing the requirement for oral and inhaled corticosteroids. This
double-blind, randomized, placebo-controlled study evaluated the safety, s
teroid-sparing effects, and impact on disease exacerbations of omalizumab i
n the treatment of childhood asthma.
Methods. Participants were 334 males and premenarchal females aged 6 to 12
years, with moderate to severe allergic asthma requiring treatment with inh
aled corticosteroids. During a run-in phase, all children were switched to
equivalent doses of beclomethasone dipropionate (BDP), and the dose was adj
usted to assure maintenance of asthma control achieved with previous cortic
osteroid treatment. Children were randomized to subcutaneously administered
placebo (N = 109) or omalizumab (N = 225) at a dose based on body weight a
nd initial serum IgE (0.016 mg/kg/IgE [IU/mL] per 4 weeks). BDP dose (initi
al range 168-420 mug/d) was kept stable for 16 weeks (stable-steroid phase)
, reduced over 8 weeks to the minimum effective dose (steroid-reduction pha
se), and maintained constant for the final 4 weeks.
Results. More participants in the omalizumab group decreased their BDP dose
, and their reduction was greater than that of the placebo group (median re
duction 100% vs 66.7%). BDP was withdrawn completely in 55% of the omalizum
ab group versus 39% of the placebo group.
The incidence and the frequency of asthma exacerbations requiring treatment
with doubling of BDP dose or systemic corticosteroids were lower in the om
alizumab group. The treatment differences were statistically significant du
ring the steroid-reduction phase, during which fewer participants in the om
alizumab group had asthma exacerbation episodes (18.2% vs 38.5%), and the m
ean number of episodes per patient was smaller than with placebo (0.42 vs 2
.72). Five asthma exacerbations requiring hospitalization all occurred in t
he placebo group.
Participants' and investigators' global evaluations of treatment effectiven
ess were more favorable for omalizumab than placebo. Investigators rated ef
fectiveness excellent for 31.5% of the omalizumab group versus 16.3% of the
placebo group and good for 44.7% of the omalizumab group versus 32.7% of t
he placebo group.
There was little change in asthma symptom scores or spirometry measurements
during either the stable-steroid or steroid dose-reduction phase, with min
imal differences between the treatment groups.
The requirement for rescue medication in the omalizumab group during both t
he stable-steroid and steroid dose-reduction phases was consistently lower
than at baseline. At week 28, the median number of puffs of rescue medicati
on taken daily was 0 in the omalizumab group and 0.46 in the placebo group.
The change from baseline was significant in favor of omalizumab.
Over the entire treatment period, patients in the omalizumab group missed a
mean of 0.65 school days, compared with a mean of 1.21 days in the placebo
group. The mean number of unscheduled medical contacts attributable to ast
hma-related medical problems was significantly smaller in the omalizumab gr
oup than in the placebo group throughout the treatment period (0.15 vs 5.35
).
Median reduction in serum free IgE was 95% to 99% among omalizumab patients
. Median free IgE ranged from 133 to 790 IU/mL at baseline and was in the r
ange of 6 to 9 IU/mL during the treatment period. The dosing scheme used in
the trial therefore effectively reduced serum IgE in patients with initial
concentrations as high as 1300 IU/mL. There was no reduction in free IgE i
n the placebo group.
Omalizumab treatment was well tolerated. There were no serious treatment-re
lated adverse events. The frequency and types of all adverse events were si
milar in the omalizumab and placebo groups. The majority of adverse events
were mild to moderate in severity. No adverse events suggestive of serum si
ckness or immune complex formation were observed. Study-drug-related advers
e events occurred more frequently in the omalizumab group than in the place
bo group (6.2% vs 0.9%). Urticaria was reported in 9 omalizumab patients (4
%) compared with 1 (0.9%) placebo patient and was mild or moderate in nearl
y all cases.
Conclusion. Treatment with omalizumab is safe in children with asthma. It r
educes the requirement for inhaled corticosteroids while protecting against
disease exacerbation.